Search
Catumaxomab
go.drugbank.com/drugs/DB06607ApprovedWithdrawnIts market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. … Catumaxumab was approved for market in Canada in May 2012 for the same condition [FDA Label]. It is currently available under the brand name Removab.
Finerenone
go.drugbank.com/drugs/DB16165ApprovedInvestigationalFinerenone, or BAY 94-8862, is a mineralocorticoid receptor antagonist indicated to reduce the risk of sustained decline in glomerular filtration rate, end stage kidney disease, cardiovascular death, heart … [A236544,L34739] Finerenone was granted FDA approval on 9 July 2021,[L34739] followed by the EMA approval on 11 March 2022.[L41449]
Homatropine
go.drugbank.com/drugs/DB11181ApprovedHomatropine is an anticholinergic drug that acts as an antagonist at muscarinic acetylcholine receptors. … It is present in antitussives, under the trade name Hycodan, in combination with hydrocodone (dihydrocodeinone) bitartrate indicated for the symptomatic relief of cough as oral tablets or solutions.
Cariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.
Synonyms: trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochlorideAdagrasib
go.drugbank.com/drugs/DB15568ApprovedInvestigationalAdagrasib (MRTX849) is an oral, small-molecule KRAS inhibitor developed by Mirati Therapeutics. … KRAS mutations are highly common in cancer and account for approximately 85% of all RAS family mutations.
Fenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnFenproporex is an orally active stimulant drug, which was developed in the 1960s. It is used as an appetite suppressant and a treatment for obesity. … prescribed in South America.
Atosiban
go.drugbank.com/drugs/DB09059ApprovedInvestigationalIt was first reported in the literature in 1985. Atosiban is licensed in proprietary and generic forms for the delay of imminent pre-term birth in pregnant adult women. … Atosiban is an inhibitor of the hormones oxytocin and vasopressin. It is used intravenously to halt premature labor.
Products: Atosiban Accord 6,75 mg/0,9 ml Injektionslösung in einer FertigspritzeTrichloroacetate
go.drugbank.com/drugs/DB11152ApprovedInvestigationalTrichloroacetate is also found in cosmetic treatments and topical formulations as a cauterant, which removes condyloma or warts on the skin. … In clinical chemistry and biochemistry, it is used as a precipitant of macromolecules including proteins, DNA and RNA.
Categories: Compounds used in a research, industrial, or household settingTyropanoic acid
go.drugbank.com/drugs/DB09340ApprovedThe molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image [L1608]. … Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac.
Categories: Compounds used in a research, industrial, or household settingDaratumumab
go.drugbank.com/drugs/DB09331ApprovedInvestigationalIn July 2024, it was further approved in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) for induction and consolidation therapy in newly diagnosed, transplant-eligible patients. … [A7935] It was first described in the literature in 2010 as a monoclonal antibody that targets CD38+ multiple myeloma cells; the first of its kind.